ClostraBio Announces Positive Results in Landmark Clinical Study with Next-Generation Probiotic CLB101™ and NutraIngredients USA 2026 Award​​

Released July 22, 2026

Women's History Month: Meet ClostraBio CEO Ritu Shah​​

Aired March 23, 2026

How a former 'part-time' CEO found a quicker time to market for a Chicago gut health startup

Published February 27, 2026

ClostraBio Fully Enrolls Placebo-Controlled Clinical Study of CLB101™, Expands Commercial Reach Through Distribution Partnership with Maypro​​

Released January 8, 2026

Maypro Partners with ClostraBio to Launch CLB101™​​

Released November 12, 2025

ClostraBio Announces Commercial Launch with Designs for Health, Initiation of Clinical Study for CLB101™, and Participation in SupplySide Global​​

Released October 24, 2025

Turning Science into Opportunity: ClostraBio's SupplySide Global Journey

Published October 1, 2025

Designs for Health Introduces Revolutionary Gut Health Supplement Anaerostipes Probiotic

Released September 24, 2025

ClostraBio Announces Key Milestones: Board Appointment of Industry Veteran Scott Ravech and Publication of CLB101™ Safety Data

Released September 16, 2025

'Biotics Trends Driving Demand in 2026

Published August 27, 2025

ClostraBio Gains Self-Affirmed GRAS Status for Next-Gen Probiotic Ingredient CLB101™

Released July 29, 2025